FDA Approval Alert: The Need-to-Know | Lisocabtagene Maraleucel in Relapsed/Refractory Follicular Lymphoma

In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel as a treatment for adult patients with relapsed/refractory follicular lymphoma following 2 or more prior lines of systemic therapy.

Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Liso-cel Earns FDA Accelerated Approval in R/R Follicular Lymphoma
Article
May 15, 2024 9:09 PM
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.